Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Cn2 toxin TFA (β-Mammal toxin Cn2 TFA) | 96.6% | 7588.60 (free base) | 1 MG
Cn2 toxin TFA (β-Mammal toxin Cn2 TFA) is a single-chain β-scorpion neurotoxic peptide and the main toxin found in scorpion venom. This peptide specifically targets mammalian voltage-gated sodium channels (VGSC) Nav1.6, making it a valuable tool for research in ion channel modulation and neurological diseases.
- Neurotoxic peptide
- Specifically targets mammalian voltage-gated sodium channels (VGSC) Nav1.6
- Functions as an ion channel modulator
- Useful in neurological disease research
- Acts as an inhibitor
Medchemexpress LLC IIQLPEIVVV TFA | 99.9% | 1122.40 | 1 MG
IIQLPEIVVV TFA is a specific inhibitor of Drp1-Mff interaction. It can distinguish physiological from pathological fission and block physiological fission, leading to mitochondrial dysfunction. It can be used in the study of Huntington's disease.
- Specific inhibitor of Drp1-Mff interaction
- Distinguishes physiological from pathological fission
- Blocks physiological fission
- Leads to mitochondrial dysfunction
- Used in the study of Huntington's disease
- Purity of 99.91%
- White to off-white solid appearance
- Sequence: Ile-Ile-Gln-Leu-Pro-Glu-Ile-Val-Val-Val
Medchemexpress LLC Crotamine TFA | 98.06% | 4883.73 (free base) | 1 MG
Crotamine TFA is a Na+ channel modulator, a 42 amino acid toxin cross-linked by three disulfide bridges. It exhibits analgesic activity and interacts with lipid membranes, showing myonecrotic activity. It can be isolated from *Crotalus durissus terrificus* venom.
- Na+ channel modulator
- 42 amino acid toxin
- Cross-linked by three disulfide bridges
- Analgesic activity
- Interacts with lipid membranes, showing myonecrotic activity
Medchemexpress LLC Men 10376 TFA | 99.7% | 1195.25 | 5 MG
Men 10376 TFA is a selective tachykinin NK-2 receptor antagonist. It exhibits a Ki of 4.4 μM for the rat small intestine NK-2 receptor, with low selectivity for NK-1 and NK-3 receptors. This compound antagonizes increases in bladder motility produced by NK-2 receptor agonists in rats.
- Selective tachykinin NK-2 receptor antagonist
- Ki of 4.4 μM for rat small intestine NK-2 receptor
- Low selectivity for NK-1 and NK-3 receptors (Ki >10 μM)
- Antagonizes bladder motility increase in vivo
Medchemexpress LLC LAGIPRA peptide (TFA) | 98.2% | 5756.50 (free base) | 5 MG
LAGIPRA peptide TFA is a long-acting GIP1R agonist that enhances insulin sensitivity by augmenting glucose disposal. It also reduces branched-chain amino acids (BCAAs) and ketoacids, making it a potential subject for research into type 2 diabetes.
- Long-acting GIP1R agonist
- Enhances insulin sensitivity by augmenting glucose disposal
- Reduces branched-chain amino acids (BCAAs) and ketoacids
- Potential for research into type 2 diabetes
Medchemexpress LLC Clovibactin TFA | 97.1% | 903.08 | 1 MG
Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027), serving as an antibiotic for drug-resistant bacterial pathogens without detectable resistance. It functions by inhibiting cell wall synthesis, specifically targeting pyrophosphate of peptidoglycan precursors.
- Effective against drug-resistant bacterial pathogens.
- No detectable resistance observed.
- Inhibits cell wall synthesis through a specific mechanism targeting peptidoglycan precursors.
- Demonstrates inhibition of Staphylococcus strains with MICs ranging from 0.125-2 μg/mL in vitro.
- Exhibits a characterized pharmacokinetic profile in mice, including a Cmax of 219.3 μg/mL and a t1/2 of 2 hours following a 20 mg/kg intravenous single dose.
Medchemexpress LLC MS9427 TFA | 98.4% | 1107.50 | 5 MG
MS9427 TFA is a potent PROTAC EGFR degrader that selectively targets and degrades mutant EGFR through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. This compound effectively inhibits the proliferation of NSCLC cells and shows antiproliferative activity against HCC-827 cells.
- Potent PROTAC EGFR degrader
- Selectively degrades mutant EGFR
- Utilizes ubiquitin/proteoteasome system and autophagy/lysosome pathways
- Inhibits proliferation of non-small cell lung cancer (NSCLC) cells
- Exhibits antiproliferative activity against HCC-827 cells
- Induces EGFRDel19 degradation
Medchemexpress LLC Ecallantide TFA | 9007-83-4 | 99.54% | 7053.81 | 50 MG
Ecallantide TFA is a specific recombinant plasma kallikrein inhibitor that works by inhibiting the production of bradykinin, thereby offering a potential treatment for acute attacks of angioedema.
- Specific recombinant plasma kallikrein inhibitor
- Inhibits the production of bradykinin
- May be used to prevent acute attacks of angioedema
Medchemexpress LLC MC-VC-PAB-NH2 TFA | 1616727-21-9 | 99.9% | 772.77 | 1 MG
MC-VC-PAB-NH2 TFA is a cleavable antibody-drug conjugate (ADC) linker, utilized in the synthesis of ADCs. ADCs are composed of an antibody to which an ADC cytotoxin is attached via an ADC linker.
- Cleavable antibody-drug conjugate linker
- Utilized in the synthesis of ADCs
- High purity of 99.9%
- Appears as a white to off-white solid
- Protease cleavable
Medchemexpress LLC MANS peptide TFA | 99.9% | 2498.83 (free acid) | 1 MG
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). It is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis.
- Inhibits migration and invasion of lung cancer cells (CL1-0/F3, CL1-5, PC9, A549) without causing toxicity to normal cells.
- Inhibits MARCKS phosphorylation and PI3K, AKT phosphorylation, leading to downstream changes in Slug and E-cadherin expression levels.
- Prevents the loss of cell-cell adhesion and alters epithelial-mesenchymal transition (EMT) characteristics of cancer cells, thereby decreasing tumor metastasis.
- Inhibits tumor metastasis without affecting tumorigenesis in PC9 xenograft NOD/SCID mice model.
